FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 187 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR A tribute to Dame Valerie Beral October 13, 2022 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... December 3, 2021 Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of... February 24, 2021 Load more HOT NEWS Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories...
